<html><head></head><body><h1>Chlophedianol and Dexbrompheniramine</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Uses</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(kloe fe DYE a nol &amp; deks brom fen EER a meen)</p><h2>Index Terms</h2><ul><li>Chlophedianol Hydrochloride and Dexbrompheniramine Maleate</li><li>D-Bromp Mal/Chlophedianol HCl</li><li>Dexbrompheniramine Maleate and Chlophedianol Hydrochloride</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p><p>Solution, Oral: </p><p>Chlo Hist: Chlophedianol hydrochloride 12.5 mg and dexbrompheniramine maleate 1 mg per 5 mL (120 mL, 473 mL) [alcohol free, dye free, gluten free, sugar free; contains propylene glycol, saccharin sodium; grape flavor]</p><h2>Brand Names: U.S.</h2><ul><li>Chlo Hist [OTC]</li></ul><h2>Pharmacologic Category</h2><ul><li>Alkylamine Derivative</li><li>Antitussive</li><li>Histamine H<sub>1</sub> Antagonist</li><li>Histamine H<sub>1</sub> Antagonist, First Generation</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Chlophedianol is an antitussive; dexbrompheniramine is an antihistamine.</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p><b>Cough and cold symptoms:</b> Temporary relief of cough due to minor throat and bronchial irritation; runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes.</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Cough and cold symptoms: </b> Oral: Chlophedianol 25 mg/dexbrompheniramine 2 mg (10 mL) every 6 hours (Maximum: Chlophedianol 100 mg/dexbrompheniramine 8 mg (40 mL) per 24 hours.</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2>Dosing: Geriatric</h2><p>Avoid use (Beers Criteria [AGS 2019]).</p><h2>Dosing: Pediatric</h2><p><b>Cough and cold symptoms: </b></p><p>Children 6 to &lt;12 years: Oral: Chlophedianol 12.5 mg/dexbrompheniramine 1 mg (5 mL) every 6 hours (Maximum: Chlophedianol 50 mg/dexbrompheniramine 4 mg (20 mL) per 24 hours.</p><p>Children ≥12 years and Adolescents: Refer to adult dosing.</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store at 15ºC to 30ºC (59ºF to 86ºF).</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Monitor therapy</i></p><p>Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Monitor therapy</i></p><p>Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Monitor therapy</i></p><p>Amphetamines: May diminish the sedative effect of Antihistamines.<i> Monitor therapy</i></p><p>Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Monitor therapy</i></p><p>Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Consider therapy modification</i></p><p>Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Monitor therapy</i></p><p>Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Consider therapy modification</i></p><p>Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Monitor therapy</i></p><p>Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Consider therapy modification</i></p><p>Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Consider therapy modification</i></p><p>Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Avoid combination</i></p><p>CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Consider therapy modification</i></p><p>CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Monitor therapy</i></p><p>Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Monitor therapy</i></p><p>Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Consider therapy modification</i></p><p>Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Avoid combination</i></p><p>Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Consider therapy modification</i></p><p>Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Monitor therapy</i></p><p>Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Monitor therapy</i></p><p>Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Avoid combination</i></p><p>Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Consider therapy modification</i></p><p>HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Monitor therapy</i></p><p>Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Monitor therapy</i></p><p>Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Consider therapy modification</i></p><p>Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Avoid combination</i></p><p>Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Consider therapy modification</i></p><p>Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Monitor therapy</i></p><p>Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Monitor therapy</i></p><p>Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Monitor therapy</i></p><p>Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Consider therapy modification</i></p><p>Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Avoid combination</i></p><p>Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Avoid combination</i></p><p>Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Consider therapy modification</i></p><p>OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Consider therapy modification</i></p><p>Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Avoid combination</i></p><p>Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Consider therapy modification</i></p><p>Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Monitor therapy</i></p><p>Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Avoid combination</i></p><p>Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Avoid combination</i></p><p>Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Avoid combination</i></p><p>Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Monitor therapy</i></p><p>Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Avoid combination</i></p><p>Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Monitor therapy</i></p><p>Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Avoid combination</i></p><p>ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Monitor therapy</i></p><p>Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Monitor therapy</i></p><p>Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Monitor therapy</i></p><p>Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Consider therapy modification</i></p><p>Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Consider therapy modification</i></p><p>Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Avoid combination</i></p><p>Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Monitor therapy</i></p><p>Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Avoid combination</i></p><p>Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Monitor therapy</i></p><p>Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Monitor therapy</i></p><p>Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Consider therapy modification</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with combination product; frequency not defined.</p><p>Central nervous system: Drowsiness, excitability (more common in children)</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p><p><b><i>Disease-related concerns:</i></b></p><p>• GU dysfunction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p><p>• Increased intraocular pressure: Use with caution in patients with increased intraocular pressure (IOP), especially narrow-angle glaucoma.</p><p>• Respiratory disease: Do not use for persistent cough (eg, smoking, asthma, or emphysema) or if cough is accompanied by excessive phlegm unless directed by a health care provider.</p><p><b><i>Special populations:</i></b></p><p>• Pediatric: Antihistamines may cause excitation in young children.</p><p><b><i>Other warnings/precautions:</i></b></p><p>• Self-medication (OTC use): Discontinue use and notify health care provider if cough or symptoms do not improve within 7 days, recur, are accompanied by fever, rash, or persistent headache, or new symptoms occur.</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Considerations</h2><p>Refer to individual monographs.</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to ease allergy signs.</p><p>• It is used to relieve coughing.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Anxiety</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Severe fatigue</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about chlophedianol / dexbrompheniramine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Drug Interactions</li>
<li>Drug class: upper respiratory combinations</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cold Symptoms</li>
<li>Cough</li>
<li>Rhinorrhea</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>